Combining hormonal therapy and tirzepatide may lead to the greatest weight loss after menopause, new evidence suggests.

The leaders of Mayo Clinic and Hormel were among the more than 60 CEOs of Minnesota-based companies who have signed a letter ...

A new study found that a combination of hormone therapy and the GLP-1 medication tirzepatide (Zepbound) led to 35% more ...

The World Health Organization reports that 1 in 8 people in the world were living with obesity in 2022. In parts of the Middle East, adult obesity rates are projected to reach nearly 40% by 2030, ...

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...

Mayo Clinic Platform names chief medical officer Gelareh Zadeh, MD, PhD, to direct clinical strategy and innovation at the ...

Heart specialists at Mayo Clinic today presented new research at the 2026 Society of Thoracic Surgeons Annual Meeting that ...

A prevention strategy developed by Canadian researchers can reduce the risk of the most common and deadly form of ovarian cancer by nearly 80 per cent. The strategy, known as opportunistic ...

Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced ...

ROCHESTER, Minn. (KTTC) – A doctor and Mayo Clinic appeared in court Friday for an ongoing lawsuit set to go to trial in ...

Dr. John R. Crockarell Elected Chief of Staff, Succeeding Dr. Frederick M. Azar Dr. Crockarell embodies the Clinic’s ...

Mayo Clinic researchers have developed a pioneering method to mend damaged hearts without open-heart surgery, an advance that could one day transform the treatment of heart failure ...